key: cord-0710979-2qcmgwnr
authors: MotieGhader, Habib; Safavi, Esmaeil; Rezapour, Ali; Amoodizaj, Fatemeh Firouzi; Iranifam, Roya asl
title: Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis
date: 2021-11-08
journal: Sci Rep
DOI: 10.1038/s41598-021-01410-3
sha: 09bba711a00adcde7ea5e0254e23f4b2c5716987
doc_id: 710979
cord_uid: 2qcmgwnr

Severe acute respiratory syndrome (SARS) is a highly contagious viral respiratory illness. This illness is spurred on by a coronavirus known as SARS-associated coronavirus (SARS-CoV). SARS was first detected in Asia in late February 2003. The genome of this virus is very similar to the SARS-CoV-2. Therefore, the study of SARS-CoV disease and the identification of effective drugs to treat this disease can be new clues for the treatment of SARS-Cov-2. This study aimed to discover novel potential drugs for SARS-CoV disease in order to treating SARS-Cov-2 disease based on a novel systems biology approach. To this end, gene co-expression network analysis was applied. First, the gene co-expression network was reconstructed for 1441 genes, and then two gene modules were discovered as significant modules. Next, a list of miRNAs and transcription factors that target gene co-expression modules' genes were gathered from the valid databases, and two sub-networks formed of transcription factors and miRNAs were established. Afterward, the list of the drugs targeting obtained sub-networks' genes was retrieved from the DGIDb database, and two drug-gene and drug-TF interaction networks were reconstructed. Finally, after conducting different network analyses, we proposed five drugs, including FLUOROURACIL, CISPLATIN, SIROLIMUS, CYCLOPHOSPHAMIDE, and METHYLDOPA, as candidate drugs for SARS-CoV-2 coronavirus treatment. Moreover, ten miRNAs including miR-193b, miR-192, miR-215, miR-34a, miR-16, miR-16, miR-92a, miR-30a, miR-7, and miR-26b were found to be significant miRNAs in treating SARS-CoV-2 coronavirus.

. The overall workflow of the proposed method. In this method, a network-based approach is applied to drug repurposing for coronavirus disease treatment. (a) At first, a transcriptome profile for healthy (control) and SARS-CoV-infected samples were taken from the GEO database with the accession number GSE1739. (b) Then, after identifying differentially expressed genes in the control and disease groups, the gene co-expression network is reconstructed, and two significant gene modules are discovered from the co-expression network. (c) Next, for every gene module, the TF-miRNA-TG network is reconstructed independently. The information of TFs-miRNAs, TFs-TGs, and miRNAs-TGs regulations are taken from the TransmiR 42 , TRRUST 39 , and miRWalk 40 www.nature.com/scientificreports/ After analyzing the network in Cytoscape software 43 , generally, 391 nodes and 1273 edges were observed in the reconstructed co-expression network. After clustering the gene co-expression network, we discovered two significant modules (Module A and Module B) in the co-expression network. The list of genes for these two modules is reported in Table 1 .

Gene co-expression network for the primary genes (disconnected genes were removed from the network). The size of the nodes indicates its degree. There are 391 nodes and 1273 edges in this network. DHX15 is the highest degree node in this network. Table 1 . Gene names of modules A and B. Numbers inside the parentheses represent the genes degree.

Module A TOP2A (24) , TTK (24) , NUSAP1 (24) , UBE2C (24) , CENPF (24) , KIF20A (24) , CDK1 (24) , CDC20 (24) , BIRC5 (24) , TRIP13 (23) , NCAPG (24) , GINS2(23), KIF11 (24) , CENPE (22) , BUB1B (24) , CCNB2 (24) , CDC25A (17) , TACC3 (17) , RAD51 (20) , TYMS (22) , CDKN3 (22) , RRM2 (24) , TK1 (19) , NEK2 (19) , PTTG1 (22) Module B SRSF1 (16) , SYNCRIP (14) , HNRNPU (16) , DHX15 (29) , SSB (19) , MATR3 (17) , GNL3 (13) , NUDT21 (16) , U2AF2 (17) , HNRNPF (17) , SRSF7 (15) , SRSF3 (17) , KHDRBS1 (14) , FUBP1 (13) , PRPF19 (14) , BYSL (12) , ILF3 (17) , NLE1 (12) , UTP6 (12) , RSL24D1 (12) , MRTO4 (13) , DIEXF (12) , PTBP1 (17) , UTP3 (12) , PWP1 (12) , PNO1 (12) , KRR1(12), NMD3 (12) , HNRNPA1 (17) , TARDBP (17) Scientific Reports | (2021) 11:21872 | https://doi.org/10.1038/s41598-021-01410-3 www.nature.com/scientificreports/ Transcription factors, miRNAs, and target genes interaction network. At first two TF-miRNA-TG sub-networks named TF-miRNA-TG_A and TF-miRNA-TG_B were reconstructed for gene modules A and B, respectively. As demonstrated in previous section, two significant gene modules were considered for more analysis. To do this, the data of TFs-TGs, TFs-miRNAs, and miRNAs-TGs regulatory interactions were retrieved from the TRRUST, TransmiR, and miRWalk databases, respectively. These two sub-networks are shown in Fig In order to analyze the TFs, which regulate more Genes and miRNAs in the TF-miRNA-TG_A and TF-miRNA-TG_B networks, the high degree TF nodes were selected and reported as significant TFs. To do this, among TF nodes in the TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks, the TFs with a degree of 10 and higher were selected ( Table 2 ). The number of TGs and target miRNAs for every TF are listed in Table 2 as well.

In addition to the TFs, a list of miRNAs that regulate more genes in the TF-miRNA-TG_A and TF-miRNA-TG_B networks were selected and reported as key miRNAs. To this end, for every TF-miRNA-TG network, five miRNAs with high degrees were assumed. These miRNAs for TF-miRNA-TG_A were hsa-miR-193b, hsa-miR-192, hsa-miR-215, hsa-miR-34a, and hsa-miR-16. For TF-miRNA-TG_B network, the selected miRNAs were hsa-miR-16, hsa-miR-92a, hsa-miR-30a, hsa-miR-7, and hsa-miR-26b. Among these miRNAs, hsa-miR-16 regulates more genes in both subnetworks. The list of these miRNAs, along with their degree and target genes, are reported in Table 3 .

Enrichment analysis of genes. Gene ontology was performed for the module A and B gene lists, separately. The results for module A gene list show that they significantly enriched in mitotic cell cycle process, nuclear division, and mitotic nuclear division biological processes. Moreover, the gene list of module B significantly enriched in RNA processing, mRNA metabolic process, and RNA metabolic process biological processes. Then, a pathway enrichment analysis was done for modules A and B gene lists separately. The results showed that the module A and B genes, significantly enriched in Resolution of Sister Chromatid Cohesion and mRNA Splicing-Major Pathway pathways, respectively. More details of the GO and pathway enrichment analyses are reported in supplementary file S3. Enrichment analysis of miRNAs. In order to check miRNA family for the TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks, at first the list of miRNAs are imported into the TAM online tool. Then, the obtained result is reported in supplementary file S4. As reported in this file, both sub-networks significantly enriched in the let-7 and mir-17 families.

After gathering drug-gene interactions for TF-miRNA-TG_A and TF-miRNA-TG_B genes, the drug-gene interaction network was reconstructed and is demonstrated in Fig. 3 . As shown in this network, some drugs have a high degree, which means that these drugs target and regulate more www.nature.com/scientificreports/ genes. Therefore, high-degree drugs were selected and reported as significant, as they regulate more genes in module_A and module_B. In this regard, the drugs with a degree of 3 or higher were selected and are reported in Table 4 . As reported, FLUOROURACIL, EPIRUBICIN, and FOSTAMATINIB are effective drugs and targeted 4, 3, and 3 genes, respectively. www.nature.com/scientificreports/ In addition to the Drug-gene interaction network, the drug-TF network was reconstructed to discover the drugs that target the transcription factors of the TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks. This network is shown in Fig. 4 . In this network, the drugs with a degree of 4 and higher were selected and reported as significant drugs. More details of the effective drugs are reported in Table 5 . As the table shows, CISPLATIN, SIROLIMUS, and CYCLOPHOSPHAMIDE drugs targeted 11, 6, and 5 TFS, respectively, and the others targeted 4 TFs. The complete information of Drug-Gene and Drug-TF interactions are provided in supplementary file S5. Additionally, supplemental file S6 has detailed information on the network topological characteristics of the Drug-Gene and Drug-TF networks.

Recently, the potential effect of 6710 drugs as SARS-CoV-2 inhibitors is tested in vitro and in vivo 44 . The results of this report show that some of the drugs proposed in this article (see Tables 4 and 5 ) have an inhibitory effect on SARS-CoV-2. According to this report, OLAPARIB, NICLOSAMID and METHOTREXATE have a very weak, weak, and strong effects on SARS-CoV-2, respectively. As well as, DAUNORUBICIN and BORTEZOMIB have a cytotoxic effect on this disease.

To evaluate the proposed drugs, the Connectivity Map(CMAP) analysis was utilized. To do this, from the Drug-Gene and Drug-TF networks, the drugs with a degree of 4 or above were selected and imported to Enrichr CMAP database. Then, the impact of these drugs on target genes was evaluated. Enrichr CMAP database contains CMAP-up and CMAP-down datasets. In Tables 3 and 4 , from among the 19 repurposed drugs for SARS-CoV disease, only nine drugs, including SIROLIMUS, METHYL-DOPA, VORINOSTAT , PACLITAXEL, DAUNORUBICIN, METHOTREXATE, NICLOSAMIDE, and ETOPO-SIDE, were validated by CMAP analysis. Table 6 shows the validated drugs together with the corresponding unregulated or downregulated target genes. www.nature.com/scientificreports/

In this article, a network-based approach was applied to discover therapeutic drugs for SARS-CoV-2 disease. Due to the high genetic similarity of SARS-CoV and SARS-CoV-2, the results of the study on SARS-CoV can be a clue to the treatment of SARS-CoV-2. To this end, at first, differentially expressed significant genes (P-value < 0.05) in healthy and SARS-CoV infected samples were selected, then the gene co-expression network was reconstructed in STRING database for the filtered genes. After reconstructing the gene co-expression network, we discovered two significant gene modules using ClusterViz plugin in Cytoscape software. These two obtained gene co-expression modules (Module A and Module B) contained 25 and 30 genes, respectively. In the next step, a list of TFs and miRNAs which regulate these module's genes were gathered from the TRRUST and miRWalk2.0 databases, respectively. Moreover, the regulation information of the TFs and miRNAs were obtained from the TransmiR database. After collecting the TFs, miRNAs, and TGs regulation information, the two sub-networks of TF-miRNA-TG_A and TF-miRNA-TG_B were reconstructed. TF-miRNA-TG_A contains 347 miRNAs, 25 TGs, and 57 TFs, and TF-miRNA-TG_B contains 116 miRNAs, 25 TGs, and 4 TFs.

To analyze the biological processes and pathways in which Module A and Module B are involved, Gene Ontology (GO) and pathway enrichment analyses were done using a DAVID tool. The GO enrichment analysis showed that the genes in Module A significantly enriched in mitotic cell cycle process, nuclear division, and mitotic nuclear division biological processes. In Module B, the genes significantly enriched in RNA processing, mRNA metabolic process, and RNA metabolic process terms. The Reactome pathway enrichment analysis showed that modules A and B enriched in Resolution of Sister Chromatid Cohesion and mRNA Splicing-Major Pathway terms, respectively (see supplementary file S3). To analyze the TF-miRNA-TG_A and TF-miRNA-TG_B sub-network's miR-NAs, the TAM online tool was utilized. Using this tool, we identified miRNAs families for these sub-networks. 

Degree Target TFs   CISPLATIN  11  BRCA2, DNMT1, E2F1, EHMT2, ESR1, MYC, MYCN, RB1, TP53, TP73   SIROLIMUS  6  APC, RB1, RBL2, TCF7L2, TP53, WT1   CYCLOPHOSPHAMIDE  5  BRCA2, CTNNB1, EHMT2, MYCN, TP53   METHYLDOPA  5  EHMT2, ESR1, HDAC1, TP53, TP73   VORINOSTAT  4  HDAC1, MYC, RB1, TP53   OLAPARIB  4  BRCA2, ESR1, MYC, TP53   MITOXANTRONE Given that the transcription factors have considerable roles in the gene expression process, the TFs of both TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks were studied and evaluated. To this end, from any TF-miRNA-TG sub-networks, the TFs with a degree of 10 and above were selected and reported. The high-degree  TFs were MYC, TP53, NFKB1, RELA, STAT3, MYCN, SP1, ESR1, E2F3, KLF4, CTNNB1, DNMT1, NANOG,  TP73, LEF1 , MYB, and FOXO3. These 17 transcription factor genes can be evaluated in further studies on SARS-CoV-2 coronavirus disease.

Hub miRNAs in TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks are essential and crucial, as they regulate more genes of the subnetworks at a post-translational regulation level and can impact biological processes. Therefore, for each TF-miRNA-TG subnetwork, five high degree miRNAs were selected and reported as significant miRNAs . Based on the findings, hsa-miR-193b, hsa-miR-192, hsa-miR-215, hsa-miR-34a , and hsa-miR-16 were significant miRNAs for TF-miRNA-TG_A subnetwork, and hsa-miR-16, hsa-miR-92a, hsa-miR-30a, hsa-miR-7, and hsa-miR-26b were found to be significant miRNAs for TF-miRNA-TG_B subnetwork as well. Among these miRNAs, hsa-miR-16 regulates more genes in both subnetworks. According to the literature, some of these miRNAs have been studied in SARS coronavirus.

Kyung Hee Choi et al. 45 found that has-miR-193 is a dual-strand tumor suppressor and a novel therapeutic target for lung cancer. In another study, Huajun Hu et al. 46 reported that this miRNA is a tumor suppressor in Non-small cell lung cancer (NSCLC). Liang Sun et al. 47 concluded that hsa-miR-193b regulates the RAB22A oncogene, inhibits breast cancer growth, and may have significant implications for cancer therapy. In addition, this miRNA regulates breast cancer cell migration and vasculogenic mimicry by DDAH1 48 . Moreover, it could function as a tumor-suppressive miRNA in breast cancer 49 and inhibits breast cancer metastasis 50 .

Martyna Filipska et al. 51 found that hsa-miR-192-5p has a functional role in squamous cell lung cancer cells. In Peng Zou et al. 52 reported that this miRNA suppresses the progression of lung cancer bone metastasis by targeting TRIM44. Moreover, this miRNA has been introduced as a prognostic marker for NSCLC participants 53 . Importantly, hsa-miR-192 induces Cisplatin-resistance, inhibits cell apoptosis in lung cancer 54 and the proliferation, migration, and invasion of osteosarcoma cells, and promotes apoptosis 55 . Xiaopan et al. 56 reported that hsa-miR-215 suppresses proliferation and migration of non-small cell lung cancer cells(NSCLC). This miRNA is downregulated in NSCLC tissues and may play a key role in the development of NSCLC. The lower expression of has-miR-215 in NSCLC is negatively associated with lymphatic metastasis and TNM staging 57 . This miRNA targets ZEB2 in human non-small cell lung cancer and functions as a tumor suppressor 58 . Ariana Centa et al. 59 expressed that has-miR-34a-5p is identified as the regulator of mRNA targets involved in endothelial, inflammatory signaling pathways, and viral diseases. Furthermore, in the present study, the expression of this miRNA was significantly down-regulated in the COVID-19 patients compared to the Controls. Also, Martin Hart et al. 60 , in their systems biology, analysis identified miR-34a as strongly associated with pathogenesis. In another study, Rieko Aida et al. 61 reported that apigenin might induce apoptosis by down-regulating SNAI1 through miR-34a-5p up-regulation in A549 cells. Woo Ryung Kim et al. 62 reported that hsa-miR-16-5p is commonly bound to SARS-CoV, MERS-CoV, and SARS-CoV-2. In Zofia Wicik et al. 63 showed that this miRNA could regulate ACE2 networks. Moreover, this miRNA can link the pathogenesis of HIV-1 and malaria [64] [65] [66] . Similarly, Jianghong Wei et al. 67 found that overexpression of miR-16 inhibited the growth and metastasis of the DMS-53 lung cancer cells. Alireza Paniri et al. 68 reported that hsa-miR-26b-5p strongly targets ACE2 and have an important effect on SARS coronavirus. Like has-miR-16-5p, has-mir-26b-5p can regulate ACE2 networks as well 63 . Moreover, this paper reported that has-miR-26b-5p may plays a significant role in the pathogenesis of HF in COVID-19 patients. The effect of this miRNA in SARS coronavirus was studied by Laura Teodori and her colleagues 69 . Moreover, Yang Gao et al. 70 reported that this miRNA plays an important role in tumor suppression in lung cancer. According to M Xia et al., this miRNA could suppress lung cancer cells' proliferation, migration, and invasion. Min Jiang et al. 71 reported that has-miR-92a family could be ideal biomarkers for cancer diagnosis and prognosis. Also, our study revealed that the expression of has-mir-92a was upregulated in lung squamous cell carcinoma (LUSC). Besides, this miRNA could promote growth, metastasis, and chemoresistance in NSCLC cells 72 . This miRNA was thus introduced as a plasma biomarker for small cell lung cancer 73 . Jianhua Gong et al. 74 revealed that the has-miR-92a up-regulation could significantly induce proliferation and inhibit apoptosis of lung cancer cells. Jianjie Zhu et al. 75 revealed that the upregulation of has-mir-30-5p in lung cancer cell lines inhibited cell proliferation in vitro and in vivo. This miRNA suppresses lung cancer progression by targeting SIRT1 76 . Also, the lack of its expression promotes the growth of lung cancer cells by targeting MEF2D. Moreover, Xiaowei Quan et al. 77 and Ruixue Tang et al. 78 revealed that miR-30a-5p expression is downregulated in NSCLC. In addition, the increase in miR-30a-5p level could enhance Bax protein level and decrease Bcl-2 protein level 77 . In the field of pharmaceutical research, Xiaojie Xu et al. 79 reported that miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Haiping Xiao et al. 80 believed that has-miR-7-5p suppresses tumor metastasis of NSCLC by targeting NOVA2. Plus, Kenneth Lundstrom 81 revealed that Rotavirus (RV) miR-7 can inhibit rotavirus replication by targeting the RV nonstructural protein 5. In another study, it was found that has-miR-7 could repress fibrogenesis of lung fibroblasts induced by TGF-β1 82 . In addition, Xiaofei Zhang et al. 83 reported that the overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer.

From the perspective of pharmacological studies, our finding shows that 470 drugs target TF and non-TF genes in both TF-miRNA-TG_A and TF-miRNA-TG_B subnetworks. Of 470 drugs, 62 drugs target both TF and non-TF genes, 95 drugs target non-TF genes, and 436 drugs target TF genes. From among the 470 obtained drugs, the drugs which target more genes were selected and discussed. In the drug-gene network, the drugs with a degree of 3 or above were selected and reported as potential and effective drugs for treating patients infected with SARS coronavirus. These drugs, including FLUOROURACIL, EPIRUBICIN, and FOSTAMATINIB www.nature.com/scientificreports/ at least three genes in the drug-gene network. Also, the drugs with a degree of 4 or above were selected and reported for the drug-TF network. These high-degree drugs were CISPLATIN, SIROLIMUS, CYCLOPHOSPHA-MIDE, METHYLDOPA, VORINOSTAT, OLAPARIB, MITOXANTRONE, FLUOROURACIL, EVEROLIMUS,  PACLITAXEL, DAUNORUBICIN, ZINC CHLORIDE, METHOTREXATE, CARBOPLATIN, BORTEZOMIB, NICLOSAMIDE, and ETOPOSIDE. Of the reported drugs, CISPLATIN targets 11 Transcription factor genes and may have a crucial impact on SARS coronavirus disease. We found that some of these drugs have been studied in SARS-CoV and SARS-CoV-2 coronaviruses, and others can be assumed as candidate drugs for SARS-CoV-2 coronavirus disease therapeutic. Shamim I. Ahmad, in his recent study, revealed that FLUOROURACIL, in combination with deoxyribose and deoxyribonucleosides, can be a therapeutic option for SARS coronavirus 84 . EPIRUBICIN, VAPREOTIDA, and SAQUINAVIR have been proposed as key drugs in SARS coronavirus treatment 85 . Also, Strich et al. 86 introduced the FOSTAMATINIB as a potential therapeutic for COVID-19. Moreover, FOSTAMATINIB has the potential to treat serious outcomes of coronavirus COVID-19, including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) 87, 88 . In addition, several studies evaluated and showed the impact of FOSTAMATINIB on SARS coronavirus [89] [90] [91] [92] . The mTOR signaling plays a crucial role in MERS-CoV infection 93 . In this regard, Yadi Zhou et al. 34 observed that the SIROLIMUS is an inhibitor of mTOR with both antifungal and antineoplastic properties. In addition, this drug has been presented as a viral protein expression blocker 94 . Swaroop Revannasiddaiaha et al. 95 showed that CYCLOPHOSPHAMIDE had a potential role in mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Moreover, Brocato et al. 96 , Othenin-Girard et al. 97 , Corso et al. 98 , Schaecher et al. 99 , and Revannasiddaiah et al. 95 evaluated and showed the impact of CYCLOPHOSPHAMIDE on SARS coronavirus disease with different approaches.

Al-Rashedi et al. 100 noted that the OLAPARIB is a potential drug for treating patients infected with SARS-COV-2. MITOXANTRONE has also been introduced as potential inhibitors of SARS-CoV-2 M pro101 . Safavi et al. 102 showed that the METHOTREXATE silence the immune activation in patients with COVID-19. Also, Sujoy Khan et al. 103 proposed this drug as a potential drug for treating patients infected with COVID-19. Additionally, this drug has a protective effect on SARS-CoV-2 infection via downregulating ACE2 104 . In this study, another drug that we have reported as a potential drug for SARS coronavirus was NICLOSAMIDE. This drug has previously been reported as an antiviral agent against COVID-19 105, 106 . Other studies have reported the potential of this drug in treating patients infected with COVID-19 107, 108 . Different studies have been undertaken on the effect of ETOPOSIDE on SARS coronavirus disease [109] [110] [111] [112] . In our previous research based on protein-protein-network analysis, we proposed PACLITAXEL, CARBOPLATIN, BORTEZOMIB, VORINOSTAT, and DAUNORUBICIN as potential drugs for SARS-CoV-2 coronavirus treatment 21 . In this study, PACLITAXEL was introduced as the most potent therapeutic candidate drug. In previous research, rare studies examined the effect of this drug on SARS-CoV-2 disease.

In conclusion, based on our results, these 19 drugs can be assumed as candidate therapeutic drugs for SARS-CoV-2 coronavirus. Moreover, along with some other drugs, nine miRNAs were proposed as candidate miR-NAs, which may play an important role in treating SARS-CoV-2 disease. These candidate miRNAs include hsa-miR-193b, hsa-miR-192, hsa-miR-215, hsa-miR-34a,hsa-miR-16, hsa-miR-92a, hsa-miR-30a, hsa-miR-7, and hsa-miR-26b.

In this study, focusing on the gene expression profile of SARS-CoV samples, an attempt was made to identify effective drugs for the treatment of this disease with a gene co-expression network-based approach. Given that the genomes of SARS-CoV and SARS-CoV-2 are very similar, it is expected that the drugs introduced to treat SARS-CoV coronavirus would also be effective in treating SARS-CoV-2 disease. Current research aimed to discover novel potential drugs for SARS-CoV disease in order to treating SARS-CoV-2 coronavirus based on a co-expression network analysis. To this end, at first, significant DEGs in normal and SARS-CoV infected samples were selected and then the gene co-expression network was reconstructed and two gene modules were discovered as significant modules. Then, two significant gene modules were discovered from the reconstructed co-expression network. Next, for the obtained modules, two sub-networks named TF-miRNA-TG_A and TF-miRNA-TG_B were drawn. Afterward, the list of the drugs targeting TF-miRNA-TG_A and TF-miRNA-TG_B sub-networks' genes was extracted, and two drug-gene and drug-TF interaction networks were drawn. Eventually, five drugs including FLUOROURACIL, CISPLATIN, SIROLIMUS, CYCLOPHOSPHAMIDE, and METHYLDOPA are proposed as poteintial drugs for SARS-CoV-2 coronavirus treatment. As well as, ten miRNAs including miR-193b, miR-192, miR-215, miR-34a, miR-16, miR-16, miR-92a, miR-30a, miR-7 , and miR-26b were found to be significant miRNAs in treating SARS-CoV-2 coronavirus.

Dataset and preprocessing. The gene expression data used in this work were downloaded from the NCBI Gene Expression Omnibus (GEO) database with the accession number GSE1739. This data contains gene expression profiles of normal and Severe Acute Respiratory Syndrome (SARS) infected patients' blood samples. To assign probes to gene IDs, the annotation file published by Affymetrix was used.

In this article, a network-based approach was applied to discover therapeutic drugs for SARS-CoV-2 disease. To this end, at first, differentially expressed significant genes (p_value < 0.05) in healthy and SARS-CoV infected samples were selected, and then the gene co-expression network was reconstructed in STRING database for the filtered genes. www.nature.com/scientificreports/ Network reconstruction and module extraction. At first, differentially expressed genes were extracted for the normal and SARS infected groups. In order to calculate the differentially expressed genes, adjusted p_ value was calculated using Benjamini & Hochberg false discovery rate method. Then, 1441 genes with p-values less than 0.05 were assumed as primary genes, which were then used in network reconstruction. The list of mentioned primary genes is reported in Supplementary file S1. Afterward, the gene co-expression network is reconstructed by primary genes in STRING database. In this web tool, the minimum required interaction score parameter is adjusted to 0.04. In order to analyze the reconstructed co-expression network, the Cytoscape software 43 version 3.8.2 was used. ClusterViz 113 plugin was used to identify gene modules (highly interconnected regions) in the co-expression network. ClusterViz is a Cytoscpae plugin, which discovers modules in a biological network using various clustering algorithms. This plugin contains three commonly used clustering algorithms, including FAG-EC, EAGLE, and MCODE.

In this research, we have applied all of the algorithms and the results did not have significant difference, so we have decided to select one of them. Therefore, the MCODE (Molecular Complex Detection) algorithm was used to find the gene co-expression modules. MCODE is a graph theoretic clustering algorithm for discovering strongly connected regions in a given network 113 . This algorithm selects the seed nodes and expand them based on the density of the cluster and density of the local neighborhood 113 . The MCODE algorithm was performed with the following parameters: Degree threshold = 2, NodeScore Threshold = 0.2, K-Core Threshold = 2, and Maxdepth = 100.

Transcription factors, miRNAs, and target genes interaction network. To investigate the effect of Transcription Factors (TF) and microRNAs (miRNA) on target genes (TG), the TF-miRNA-TG sub-networks were reconstructed for gene modules.

Transcription factors (TF) are proteins that regulate the rate of transcription of genetic information from DNA to messenger RNA 114 . miRNAs are small non-coding RNAs that function in RNA silencing and post-transcriptional gene regulation 23, 115 . Both TFs and miRNAs regulate gene expression 116 . To get regulatory interactions information of TFs-TGs, the TRRUST online database was utilized. This database contains 8,444 and 6,552 TF-target regulatory relationships of 800 human TFs and 828 mouse TFs, respectively. In addition to TFs-TGs regulatory information, TFs-miRNAs regulatory interactions are essential. This information is obtained from the TransmiR V2 42 database. TransmiR v2.0 incorporates 3,730 TF-miRNA regulatory interactions, covering 623 TFs and 785 miRNAs for 19 organisms. In this study, the information of miRNAs-TGs regulatory interactions was retrieved from the miRWalk 2.0 database. This database contains both validated and predicted interactions. In this study, only experimentally validated miRNAs-TGs interactions were considered.

In order to analyze the reconstructed co-expression network, the Cytoscape software was used. After analyzing the network, generally, 391 nodes and 1273 edges were observed in the reconstructed co-expression network. ClusterViz 113 plugin was used to identify gene modules (highly interconnected regions) in the co-expression network. ClusterViz is a Cytoscpae plugin, which discovers modules in a biological network using various clustering algorithms. This plugin contains three commonly used clustering algorithms, including FAG-EC, EAGLE, and MCODE. The MCODE (Molecular Complex Detection) algorithm was used to find the gene co-expression modules in this study. The MCODE algorithm was performed with the following parameters: Degree threshold = 2, NodeScore Threshold = 0.2, K-Core Threshold = 2, and Maxdepth = 100. After clustering the gene co-expression network, we discovered two significant modules (Module A and Module B) in the co-expression network. Enrichment analysis. The Database for Annotation, Visualization, and Integrated Discovery (DAVID ) v6. 8 117,118 was used for the enrichment analysis of the genes. The gene ontology and pathway enrichment analysis were done for obtained gene modules.

To identify miRNAs family, the TAM online tool 119 was applied. To do this, all the miRNAs in TF-miRNA-TG sub-networks were imported to the TAM tool separately, and then significant miRNA families were identified.

To identify the drugs that target TF-miRNA-TG_A and TF-miRNA-TG_B TF and non-TF genes, the Drug Gene Interaction Database (DGIdb) 41 was used. This database retrieves drug-gene interaction information from 24 other related databases. In this study, to identify drug-genes interaction, only approved drugs were used. GSEA and candidate drugs validation. In order to evaluate the proposed drugs for SARS-CoV-2 disease, the GSEA was performed by querying the Enrichr database 120 . To this end, the Enrichr database was utilized to perform the Connectivity Map(CMAP) analysis 121 www.nature.com/scientificreports/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

Origin and evolution of pathogenic coronaviruses

The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis

SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Integrative transcriptome analyses empower the anti-COVID-19 drug arsenal

A novel coronavirus from patients with pneumonia in China

Sequential and mixed genetic algorithm and learning automata (SGALA, MGALA) for feature selection in QSAR. Iran

Endocrine disrupting chemicals and COVID-19 relationships: A computational systems biology approach

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection

Consider TLR5 for new therapeutic development against COVID-19

The aging immune system and its relationship to the development of chronic obstructive pulmonary disease

Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Overly exuberant innate immune response to SARS-CoV-2 infection

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections 9

Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective

Gene biomarker discovery at different stages of Alzheimer using gene coexpression network approach

Gene co-expression network approach for predicting prognostic microRNA biomarkers in different subtypes of breast cancer

Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis

Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis

mRNA-miRNA bipartite network reconstruction to predict prognostic module biomarkers in colorectal cancer stage differentiation

A. mRNA and microRNA selection for breast cancer molecular subtype stratification using meta-heuristic based algorithms

Drug repurposing (DR): an emerging approach in drug discovery

Drug repurposing: progress, challenges and recommendations

A paradigm shift in medicine: A comprehensive review of network-based approaches

SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19

SAveRUNNER: an R-based tool for drug repurposing

Drug repurposing: a network-based approach to amyotrophic lateral sclerosis

In silico drug repurposing in COVID-19: a network-based analysis

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Network-based virus-host interaction prediction with application to SARS-CoV-2

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

Construction of an autophagy interaction network based on competitive endogenous RNA reveals the key pathways and central genes of SARS-CoV-2 infection in vivo. Microb

STRING 8-a global view on proteins and their functional interactions in 630 organisms

TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions

0: a comprehensive atlas of microRNA-target interactions

Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts

TransmiR: a transcription factor-microRNA regulation database

Cytoscape: a software environment for integrated models of biomolecular interaction networks

Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In

Dual-strand tumor suppressor miR-193b-3p and-5p inhibit malignant phenotypes of lung cancer by suppressing their common targets

MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells

Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes

MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1

CD44v6 targeted by miR-193b-5p in the coding region modulates the migration and invasion of breast cancer cells

Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics

MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma

miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44

Dysregulation of exosomal miR-192 and miR-194 expression in lung adenocarcinoma patients

MiR-192 confers cisplatin resistance by targeting Bim in lung cancer

MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

MicroRNA-215 suppresses the proliferation, migration and invasion of non-small cell lung carcinoma cells through the downregulation of matrix metalloproteinase-16 expression

miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer

Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients

Identification of miR-34a-target interactions by a combined network based and experimental approach

miR-34a-5p might have an important role for inducing apoptosis by down-regulation of SNAI1 in apigenin-treated lung cancer cells

Expression Analyses of MicroRNAs in Hamster Lung Tissues Infected by SARS-CoV-2

ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors

Correction to: Role of microRNAs in host defense against Echinococcus granulosus infection: a preliminary assessment

Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection

The characterization of extracellular vesicles-derived microRNAs in Thai malaria patients

MicroRNA-16 inhibits the proliferation and metastasis of human lung cancer cells by modulating the expression of YAP1

Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations

MicroRNAs bioinformatics analyses identifying HDAC pathway as a putative target for existing anti-COVID-19 therapeutics

MiR-26b regulates invasion and migration of lung cancer cells through targeting hENT1 depending on RhoA/ ROCK-1 pathway. Zhong nan da xue xue bao

MiR-92a family: a novel diagnostic biomarker and potential therapeutic target in human cancers

MicroRNA-92a promotes growth, metastasis, and chemoresistance in nonsmall cell lung cancer cells by targeting PTEN

Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark

The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance

CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer

miR-30a suppresses lung cancer progression by targeting SIRT1

p53/miR-30a-5p/SOX4 feedback loop mediates cellular proliferation, apoptosis, and migration of non-small-cell lung cancer

Downregulation of MiR-30a is associated with poor prognosis in lung cancer

miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression

MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2

The CDR1as/miR-7/TGFBR2 axis modulates EMT in silica-induced pulmonary fibrosis

Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer

5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection

Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study

Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic

Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury

A high content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury during the COVID-19 pandemic

Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19

Drug repurposing for COVID-19 treatment by integrating network pharmacology and transcriptomics

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic

A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Medi

Disruption of adaptive immunity enhances disease in SARS-CoV-2-infected Syrian hamsters

Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult

Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapy

An immunosuppressed Syrian golden hamster model for SARS-CoV infection

Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing

Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19

Silencing of immune activation with methotrexate in patients with COVID-19

Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword

Does methotrexate influence COVID-19 infection? Case series and mechanistic data

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19

Niclosamide-clay intercalate coated with nonionic polymer for enhanced bioavailability toward COVID-19 treatment

Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide

Etoposide-based therapy for severe forms of COVID-19

Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19

Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients

The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients

ClusterViz: a cytoscape APP for cluster analysis of biological network

Genome-wide analysis of microRNA and mRNA expression signatures in cancer

MicroRNA-transcription factor interactions and their combined effect on target gene expression in colon cancer cases

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

TAM 2.0: tool for MicroRNA set analysis

Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

This work was supported by the Islamic Azad University, Tabriz branch.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-01410-3.Correspondence and requests for materials should be addressed to H.M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.